Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Drmic et al., 2017, 2018
Biological Activity Cagrilintide and semaglutide, when co-administered, produce synergistic reductions in bodyweight (up to ~1517% over 2032 weeks in clinical trials) and significant improvements in glycemic parameters, including HbA1c and fasting glucose
Patients achieved substantial weight loss during the initial GLP-1 RA phase (~1822% at 12 months), which was subsequently maintained after its discontinuation, with total weight reduction reaching 25.5% (95% CI 23.127.9%) at 593 days, with most patients on metformin
Observational studies and case series have demonstrated that GLP-1 agonists can effectively reduce HbA1c by 0.51.5% and facilitate weight loss in kidney, liver, and heart transplant recipients, with safety profiles comparable to non-transplant populations
It is a fantastic choice for individuals whose primary challenge is managing portion sizes and cravings
